BVS
Bioventus Inc.
BVS's fundamentals are strong: free cash flow grew 59% and earnings per share more than tripled. At 14x earnings, it's trading about half its usual 27x. Analysts expect that strong growth to continue.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
BVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $10.86 | — |
| Current | 14x | $10.86 | — |
| Cheap | 18x | $14.37 | +32% |
| Fair | 26x | $21.13 | +95% |
| Expensive | 69x | $54.91 | +406% |
Historical ranges are pointers, not guarantees.
BVS's PE is in its cheap range at 14x. On analysts' estimates for next year's earnings, today's price would be 13x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BVS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
BVS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +1.6% |
| Q3 2026 | $0.80 | +627% |
| Q2 2026 | $0.77 | +$0.78 |
| Q1 2026 | $0.41 | +$0.90 |
| Q4 2025 | $0.33 | +$0.85 |
| Q3 2025 | $0.11 | +$0.69 |
| Q2 2025 | -$0.01 | +$0.62 |
| Q1 2025 | -$0.49 | -$0.17 |
| Q4 2024 | -$0.52 | +$1.97 |
BVS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $142.4M | +2.7% |
| Q2 2026 | $153.2M | +3.8% |
| Q1 2026 | $132.1M | +6.6% |
| Q4 2025 | $157.9M | +2.8% |
| Q3 2025 | $138.7M | -0.2% |
| Q2 2025 | $147.7M | -2.4% |
| Q1 2025 | $123.9M | -4.3% |
| Q4 2024 | $153.6M | +13% |
BVS's revenue grew through 2024 and has held roughly level since: $142M last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | -1.3 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | 6.4% | +2.4 points |
| Q4 2025 | 12% | +7.1 points |
| Q3 2025 | 8.1% | +5.2 points |
| Q2 2025 | 12% | +32 points |
| Q1 2025 | 3.9% | -0.2 points |
| Q4 2024 | 5.2% | +4.3 points |
BVS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.3M | -31% |
| Q2 2026 | $18.9M | -25% |
| Q1 2026 | $8.4M | +$28.5M |
| Q4 2025 | $37.4M | +99% |
| Q3 2025 | $29.6M | +189% |
| Q2 2025 | $25.3M | +67% |
| Q1 2025 | -$20.2M | -$13.9M |
| Q4 2024 | $18.7M | +87% |
BVS generated $85M in free cash flow over the past year, up 59% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BVS on cash flow, with more consistent year-over-year improvement.
BVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +1.7M shares |
| 1 year | +5.3% | +3.7M shares |
| 3 years | +15% | +9.7M shares |
| 5 years | +73% | +30.7M shares |
| Available history | +30% | +16.9M shares |
BVS has 72M diluted shares, up 5.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 4.9x | High |
| Q1 2025 | 20.2x | High |
| Q4 2024 | 18.0x | High |
BVS's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
BVS's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BVS PE vs Healthcare Sector
| Metric | BVS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 2 | 35 | 33 pts below |
BVS is trading at 14x earnings, a 48% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 16% below |
| 20 week MA | $13.0 | 16% below |
| 50 week MA | $10.4 | 4.4% above |
| 100 week MA | $9.16 | 19% above |
| 200 week MA | $7.20 | 51% above |
BVS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.2 | $14.0 | -19% |
| 2022 | $14.0 | $2.54 | -82% |
| 2023 | $2.54 | $5.27 | +107% |
| 2024 | $5.27 | $10.6 | +102% |
| 2025 | $10.6 | $7.46 | -30% |
| 2026 YTD | $7.46 | $10.9 | +46% |
BVS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.